Platelet response to prasugrel and clopidogrel loadinig doses in elective PCI patients
Not Applicable
- Conditions
- Elective PCI
- Registration Number
- JPRN-UMIN000017624
- Lead Sponsor
- Division of Cardiovascular Medicine, Jichi Medical University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
(1)Concomitant use of other antiplatelet drugs other than aspirin. (2)Participation in other clinical trial. (3)Platelet counts of <10x107/ml or >40x107/ml (4)Malignant disease or autoimmune disease. (5)Judgment by physician that a patient is inappropriate to enroll the study. (6)Patient who have communication difficulty.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Responses of platelets to the treatment with prasugrel and clopidogrel.
- Secondary Outcome Measures
Name Time Method To investigate the frequency of bleeding complication such as gross hematuria,subcutaneous bleeding,hemoglobin change after percutaneous coronary intervention.